NASDAQ
26.01.26 | 22:00
2,800 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 15.12.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals GAAP EPS of -$0.37 | 3 | Seeking Alpha | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 13.10.25 | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| 01.10.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 101 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.09.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 158 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.08.25 | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08.25 | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08.25 | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 181 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 134 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.05.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 203 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.04.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 202 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03.25 | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 227 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
| 03.03.25 | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 185 | GlobeNewswire (Europe) | SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 03.02.25 | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 202 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule... ► Artikel lesen | |
| 29.01.25 | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | 705 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 40,230 | -0,38 % | Moderna: Rallye läuft heiß - Warnsignale im Chart | Moderna profitiert von positiven Studiendaten und einer starken Kursbewegung seit Jahresbeginn. Kommt nach der steilen Rallye nun eine Konsolidierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| VALNEVA | 3,990 | +0,86 % | Valneva zieht US-Zulassungsanträge für IXCHIQ zurück - Aktie unter Druck | Die Valneva SE hat die Zulassungsanträge (BLA und IND) für ihren Chikungunya-Impfstoff IXCHIQ in den USA freiwillig zurückgezogen. Hintergrund sind regulatorische Maßnahmen der U.S. Food and Drug Administration... ► Artikel lesen | |
| NOVAVAX | 8,122 | +0,27 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,410 | +2,50 % | NurExone Biologic: Fortschritte in Milliardenmarkt für Rückenmarksverletzungen | ||
| IMMUNITYBIO | 5,098 | -2,37 % | ImmunityBio-Aktie: Jetzt noch mit der Kursrakete mitfliegen? | Die ImmunityBio-Aktie machte einen Raketenstart ins neue Jahr. Bis gestern schoss der Kurs des Biotech-Unternehmens von 2,00 auf 5,50 US$ hoch. Doch am Dienstagmorgen bricht der Biotech-Titel im europäischen... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,960 | -20,97 % | Krebs-Impfstoff: Chance Teil 2: Phase-2-Start für den Brustkrebs-Impfstoff und starke CAR-T-Daten bei Eierstockkrebs.Wird 2026 der Wendepunkt? | ||
| ALDEYRA | 4,340 | -1,32 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,420 | -0,35 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| GUARDANT HEALTH | 95,36 | -1,28 % | FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer | ||
| COHERUS ONCOLOGY | 1,890 | -1,74 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| OCULAR THERAPEUTIX | 8,850 | -3,49 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer | Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA- while at Regeneron Most recently served as Chief Marketing... ► Artikel lesen | |
| ESPERION | 2,851 | +1,28 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,360 | -0,36 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| MACROGENICS | 1,509 | -1,76 % | MacroGenics, Inc.: MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress | Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealigned... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.